Till now, two PD-1-targeting antibodies, pembrolizumab [41] and nivolumab [42], have received FDA approval for HCC under specific conditions, marking significant progress in PD-1-targeted therapy for liver cancer (Table 1). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.